Results of a Phase 1/2a dose–escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes

Abstract FF-10501-01 potently inhibits inosine-5-monophosphate dehydrogenase (IMPDH), inducing anti-proliferative and pro-apoptotic effects in acute myeloid leukemia (AML) human cell lines resistant to hypomethylating agents. In this Phase 1/2a study, Phase 1 enrolled 38 patients with relapsed/refractory AML (n = 28) or myelodysplastic syndromes (MDS/CMML, n = 10) to receive FF-10501 oral doses 50–500 mg/m2 BID for 14 or 21 days out of each 28-day cycle. Fifteen additional patients with HMA-resistant MDS/CMML (Phase 2a) were treated at 400 mg/m2 BID for 21 days. Most Phase 1 adverse events were disease-related and low-grade. 3 of 19 (16%) evaluable AML patients achieved partial remission (31, 7, and 5 months). 2 of 20 (10%) evaluable MDS/CMML patients (Phase 1 and 2a) attained marrow complete remission, one continuing treatment for 17 months. While FF-10501-01 demonstrated clinical activity and target inhibition in heavily pretreated patients with AML and MDS/CMML, increased mucositis events led to Phase 2a closure (ClinTrials.gov#NCT02193958).

[1]  L. Pleyer,et al.  Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. , 2018, Blood advances.

[2]  Tae Kon Kim,et al.  Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. , 2018, Blood advances.

[3]  Y. Kanakura,et al.  Molecular targeting of inosine-5’-monophosphate dehydrogenase by FF-10501 promotes erythropoiesis via ROS/MAPK pathway , 2018, Leukemia & lymphoma.

[4]  G. Garcia-Manero,et al.  Preclinical activity of FF-10501-01, a novel inosine-5'-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia. , 2017, Leukemia research.

[5]  Y. Hayashi,et al.  Inhibition of Impdh As an Effective Treatment for MLL-Fusion Leukemia , 2016 .

[6]  J. Barnard,et al.  The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure , 2016, Haematologica.

[7]  Y. Shimada,et al.  Lack of cross‐resistance to FF‐10501, an inhibitor of inosine‐5′‐monophosphate dehydrogenase, in azacitidine‐resistant cell lines selected from SKM‐1 and MOLM‐13 leukemia cell lines , 2016, Pharmacology research & perspectives.

[8]  M. Konopleva,et al.  Survival Outcomes in Relapsed/Refractory Acute Myeloid Leukemia Patients Who Achieve Less-than-Complete Response After First Salvage Therapy , 2014 .

[9]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[10]  B. Esterni,et al.  Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Strovel,et al.  A phase I trial of AVN944 in patients with advanced hematologic malignancies , 2007 .

[12]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[13]  J. Sherley,et al.  Immortal DNA strand cosegregation requires p53/IMPDH-dependent asymmetric self-renewal associated with adult stem cells. , 2005, Cancer research.

[14]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Grusch,et al.  Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis. , 1999, Current medicinal chemistry.

[16]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[17]  F. Collart,et al.  Increased IMP dehydrogenase gene expression in solid tumor tissues and tumor cell lines , 1992 .

[18]  N. Heerema,et al.  Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity. , 1989, Cancer research.

[19]  K. Yamada,et al.  [Phase II study of SM-108 (4-carbamoylimidazolium-5-olate) in hematological malignancies]. , 1989, Gan to kagaku ryoho. Cancer & chemotherapy.